The findings revealed no discernible disparity in intracellular ROS levels between NLRP4-knockdown pancreatic cancer cells and control cells treated with MitoQ (Fig. 7a, b and Extended Data Fig. 7a, b). This evidence concerns the gene NLRP4 and pancreatic neoplasm.